HOME > TOP STORIES
TOP STORIES
-
BUSINESS Vibegron Prescription Soars after 14-Day Limit Lifted, Triggering Shipment Curbs
April 16, 2020
-
BUSINESS Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief
April 16, 2020
-
BUSINESS Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
-
BUSINESS Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
-
BUSINESS Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
April 15, 2020
-
ORGANIZATION FPMAJ Ups Ante for Drug Supply Coordination amid COVID-19 Crisis
April 14, 2020
-
BUSINESS Tokushukai Preparing Model Formulary for 72 Group Hospitals; PPIs, Flu Drugs Eyed
April 14, 2020
-
REGULATORY Health Minister Vows to Shorten Review Time for Avigan
April 14, 2020
-
REGULATORY MSD’s 9-Valent HPV Vaccine Nearing Finish Line in Japan 5 Years after Filing, but Vaccination Policy Remains Iffy
April 13, 2020
-
BUSINESS After Valsartan, Towa Now Curbing Clindamycin Supplies as India Lockdown Continues
April 13, 2020
-
BUSINESS Chugai Shifting Resources to Beef Up Drug Discovery Prowess: New Chief
April 13, 2020
-
BUSINESS Sanofi Launches Kevzara Trial for Severe COVID-19 in Japan
April 10, 2020
-
BUSINESS Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
-
BUSINESS Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
-
REGULATORY Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
April 9, 2020
-
BUSINESS Chugai to Launch Actemra PIII Trial for Coronavirus
April 9, 2020
-
REGULATORY Japan Books 13.9 Billion Yen to Boost Avigan Stockpile, Abe Vows to Expand Access to Fujifilm Drug
April 8, 2020
-
BUSINESS Rush to BCG Vaccine for COVID-19 Leads to Curbs on Shipments
April 7, 2020
-
BUSINESS Big 3 Generic Maker Curbing Valsartan Shipments amid India Lockdown
April 6, 2020
-
REGULATORY Japan’s Stimulus Package Likely to Support API Manufacturing Repatriation, Vaccine/Drug Development
April 3, 2020
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
